Zacks Investment Research
11 Dec 2025, 18:01 UTC · 40w ago
Verdict
Source says Upgrade to Buy. We score ELTX +0.80 across one claim.
Score confirms the headline.
Upgrade to Buy
Rating stated in the headline
+0.80strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish
Elicio Therapeutics (ELTX) has been upgraded to a Zacks Rank #2 (Buy).
So whatThe upgrade is driven by an upward trend in earnings estimates, which the text claims is strongly correlated with near-term stock price increases.
More positive than 77% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 86% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 86% of ticker scores this week
The company received a Zacks Rank upgrade to #2 (Buy) based on an upward trend in earnings estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−76.8%
Price is moving against the score
$1.87 vs $8.05 close before publication (Dec 10) · not market-adjusted
ELTX chart →
